{
    "clinical_study": {
        "@rank": "45176", 
        "arm_group": [
            {
                "arm_group_label": "Part I SAD", 
                "arm_group_type": "Experimental", 
                "description": "SAD: intravenous (IV) and subcutaneous (SC) doses of BG00010 or placebo in Healthy Volunteers"
            }, 
            {
                "arm_group_label": "Part II Extended SAD", 
                "arm_group_type": "Experimental", 
                "description": "Extended SAD: intravenous (IV) and subcutaneous (SC) doses of BG00010 or placebo in Healthy Volunteers"
            }, 
            {
                "arm_group_label": "Part III MAD", 
                "arm_group_type": "Experimental", 
                "description": "MAD: subcutaneous (SC) doses of BG00010 or placebo in subjects with painful lumbar radiculopathy"
            }, 
            {
                "arm_group_label": "Part IV Extended MAD", 
                "arm_group_type": "Experimental", 
                "description": "Extended MAD: subcutaneous (SC) doses of BG00010 or placebo in subjects with painful lumbar radiculopathy"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to evaluate the safety and tolerability of a range of\n      single Intravenous (IV) and Subcutaneous (SC) doses of BG00010 in healthy volunteers, and a\n      range of multiple subcutaneous (SC) doses of BG00010 in subjects with painful lumbar\n      radiculopathy.\n\n      Secondary objectives of this study are:\n\n        -  To determine the single IV and SC dose pharmacokinetics (PK) profile of BG00010 in\n           healthy volunteers including assessment of    bioavailability by comparing subcutaneous\n           (SC) exposure to IV exposure in each subject.\n\n        -  To determine the multiple subcutaneous (SC) dose PK profiles of BG00010 in subjects\n           with painful lumbar radiculopathy.\n\n        -  To assess the single IV and subcutaneous (SC) dose immunogenicity of BG00010 in healthy\n           volunteers.\n\n        -  To assess the multiple SC dose immunogenicity of BG00010 in subjects with painful\n           lumbar radiculopathy.\n\n        -  To assess the potential of BG00010 to reduce pain following multiple SC administrations\n           in subjects with painful lumbar radiculopathy."
        }, 
        "brief_title": "Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Painful Lumbar Radiculopathy", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Pain", 
                "Radiculopathy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: Part I and Part II\n\n          -  Healthy Volunteers\n\n        Inclusion Criteria: Part III (MAD) and Part IV (Extended MAD)\n\n          -  Subjects must have a diagnosis of unilateral painful lumbar radiculopathy and painful\n             lumbar radiculopathy symptoms must be      present for 3 or more months prior to the\n             Screening Visit.\n\n          -  Subjects must rate their pain at \u226540 mm on the 100 mm visual analog scale (VAS) of\n             the short form McGill pain questionnaire (SF-MPQ) at the Screening and Baseline\n             Visits.\n\n        Inclusion Criteria for All Subjects for Part I, Part II, Part III, Part IV:\n\n          -  All male subjects and all female subjects of childbearing potential must practice\n             effective contraception during the study and be willing and able to continue\n             contraception for 3 months after their last dose of study treatment. -\n\n        Exclusion Criteria for All Subjects for Part I, Part II, Part III, Part IV:\n\n          -  History of or positive screening test for hepatitis C infection , hepatitis B\n             infection, or positive for human immunodeficiency virus (HIV) antibody. Subjects who\n             are HBsAg negative and HBcAb positive are allowed to participate if they are positive\n             for HBsAb immunoglobulin G\n\n          -  History of malignancy or clinically relevant (as determined by the Investigator)\n             allergies; cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic,\n             urologic, pulmonary, neurologic (not related to painful lumbar radiculopathy),\n             dermatologic, rheumatic/joint, psychiatric, renal, and/or other major disease.\n\n          -  Relevant history of illicit drug or alcohol abuse (as defined by the Investigator)\n             within 1 year prior to the Screening Visit. -\n\n          -  Female subjects who are pregnant or currently breastfeeding, or who have a positive\n             pregnancy test result at the Screening or Baseline Visits.\n\n          -  Previous administration of a neurotrophic factor, including BG00010.\n\n          -  Participation in a study with another investigational drug or approved therapy for\n             investigational use within the 3 months prior to the Baseline Visit, or current\n             enrollment in any other study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842126", 
            "org_study_id": "103NS103"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part I SAD", 
                    "Part II Extended SAD"
                ], 
                "description": "Ascending Doses subcutaneous (SC) or intravenous (IV) of BG00010 (Part I SAD & Part II Extended SAD)", 
                "intervention_name": "BG00010", 
                "intervention_type": "Biological", 
                "other_name": "Neublastin"
            }, 
            {
                "arm_group_label": [
                    "Part III MAD", 
                    "Part IV Extended MAD"
                ], 
                "description": "Ascending Doses subcutaneous (SC) of BG00010 (Part III MAD & Part IV Extended MAD)", 
                "intervention_name": "BG00010", 
                "intervention_type": "Biological", 
                "other_name": "Neublastin"
            }, 
            {
                "arm_group_label": [
                    "Part I SAD", 
                    "Part II Extended SAD"
                ], 
                "description": "Ascending Doses subcutaneous (SC) or intravenous (IV) of Placebo (Part I SAD & Part II Extended SAD)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part III MAD", 
                    "Part IV Extended MAD"
                ], 
                "description": "Ascending Doses subcutaneous (SC) of placebo (Part III MAD & Part IV Extended MAD)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Sciatica", 
        "lastchanged_date": "April 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leiden", 
                    "country": "Netherlands"
                }, 
                "name": "Center for Human Drug Research"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "4", 
        "official_title": "Study of Safety, Tolerability, and Pharmacokinetics of BG00010 (Neublastin) Intravenous and Subcutaneous Single Ascending Doses in Healthy Volunteers, and Subcutaneous Multiple Ascending Doses in Subjects With Painful Lumbar Radiculopathy", 
        "overall_contact": {
            "email": "neurologyclinicaltrials@biogenidec.com", 
            "last_name": "Biogen Idec"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Day 75 for each group/arm"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842126"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum observed concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 75"
            }, 
            {
                "measure": "Time to maximum serum concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 29"
            }, 
            {
                "measure": "Half life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 29"
            }, 
            {
                "measure": "Area under the serum concentration time curve (AUC) from zero to infinity AUC(0-\u221e)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 29"
            }, 
            {
                "measure": "Subcutaneous (SC) bioavailability", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 29"
            }, 
            {
                "measure": "Incidence of anti-BG00010 antibodies in serum", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 75"
            }, 
            {
                "measure": "Pain, as measured by an 11-point NRS, and by the VAS of SF-MPQ", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 75"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}